UNLOCKING POTENTIAL: HOW SERUM L1EV Α-SYNUCLEIN MAY REVOLUTIONIZE PARKINSON’S DIAGNOSTICS
DOI:
https://doi.org/10.55519/JAMC-02-13000Keywords:
Parkinson’s Disease, Serum L1EV α-synuclein levels, Prodromal Diagnosis, Biomarker, NeurodegenerationAbstract
Parkinson’s Disease (PD) poses many challenges and the urgent need for early diagnosis, emphasizing the limitations of motor symptoms in providing timely detection is imperative. The MDS research criteria, including motor changes, non-motor symptoms, and dopaminergic functional imaging findings, are crucial markers for prodromal PD diagnosis. Shijun Yan et al. recent study introduces serum L1EV α-synuclein levels as a potential biomarker, detecting early pathogenesis shifts, serving as a cost-effective and accessible tool for screening high-risk individuals. The benefits of this multi-marker approach benefits in evaluating disease prognosis and progression. Serum L1EV α-synuclein's role in uncovering non-motor features, such as depression and anxiety, in prodromal PD underscores its significance for improving patient quality of life. The potential for early intervention using this biomarker offers hope for halting neurodegeneration and delaying clinical PD development. The global applicability of this promising biomarker needs to be looked into, while the need for more diverse racial and ethnic studies regarding it are required. Ultimately, the letter argues that identifying high-risk individuals through L1EV α-synuclein enables timely neuroprotective interventions, providing patients with valuable insights into disease progression and reducing uncertainty and fear.References
Beitz JM. Parkinson’s disease: a review. Front Biosci (Schol Ed) 2014;6(1):65–74.
Berg D, Borghammer P, Fereshtehnejad SM, Heinzel S, Horsager J, Schaeffer E, et al. Prodromal Parkinson disease subtypes — key to understanding heterogeneity. Nat Rev Neurol 2021;17(6):349–61.
Yan S, Jiang C, Janzen A, Barber TR, Seger A, Sommerauer M, et al. Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease. JAMA Neurol 2024;81(1):59–68.
Ray S, Agarwal P. Depression and Anxiety in Parkinson Disease. Clin Geriatr Med 2020;36(1):93–104.
Van Den Heuvel L, Hoefsloot W, Post B, Meinders MJ, Bloem BR, Stiggelbout AM, et al. Professionals’ Treatment Preferences in the Prodromal Phase of Parkinson’s Disease: A Discrete Choice Experiment. J Parkinsons Dis 2022;12(5):1655–64.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Tabeer Zahid, Rayyan Nabi, Hanzala Ahmed Farooqi
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
